Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML - Trial NCT06232694
Access comprehensive clinical trial information for NCT06232694 through Pure Global AI's free database. This phase not specified trial is sponsored by The First Affiliated Hospital with Nanjing Medical University and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 54 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;
Interventional
drug
Sponsor & Location
The First Affiliated Hospital with Nanjing Medical University
Timeline & Enrollment
N/A
Jan 01, 2024
Dec 30, 2027
Primary Outcome
The composite complete remission rate (CR+CRi)
Summary
This study evaluates the efficacy and safety of the combination of idarubicin and cytarabine
 induction followed by intermediate-dose cytarabine consolidation with venetoclax in the
 treatment of newly diagnosed adult acute myeloid leukemia (AML).
 
 This study includes the induction and consolidation phases of AML treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06232694
Non-Device Trial